Guidance published on conducting medicinal clinical trials during coronavirus (COVID-19)

Guidance published on conducting medicinal clinical trials during coronavirus (COVID-19)

The Medicines and Healthcare products Regulatory Agency has published guidance for trial sponsors setting out how they can minimise disruptions to the conduct and integrity of clinical trials of medicines during the coronavirus (COVID-19) pandemic. The aim of the guidance is to support trial sponsors building resilience into clinical trial design.

Source: Guidance on minimising disruptions to the conduct and integrity of clinical trials of medicines during COVID-19

Related Articles:
Latest Articles: